The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions
Onyinye Ugonabo, Utibe‐Abasi S. Udoh, Pradeep Rajan, Heather Reeves, Christina Arcand, Yuto Nakafuku, Tejas Joshi, Rob Finley, Sandrine V. Pierre, Juan Sanabria
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is one of the major risk factors for chronic liver disease and hepatocellular carcinoma (HCC). The incidence of MASH in Western countries continues to rise, driving HCC as the third cause of cancer-related death worldwide. HCC has become a major global health challenge, partly from the obesity epidemic promoting metabolic cellular disturbances but also from the paucity of biomarkers for its early detection. Over 50% of HCC cases are clinically present at a late stage, where curative measures are no longer beneficial. Currently, there is a paucity of both specific and sensitive biological markers for the early-stage detection of HCC. The search for biological markers in the diagnosis of early HCC in high-risk populations is intense. We described the potential role of surrogates for a liver biopsy in the screening and monitoring of patients at risk for nesting HCC.